SightGlass Vision
SightGlass Vision is a medical device company that develops DOT (Diffusion Optics Technology) spectacle lenses to slow myopia progression in children aged 6–13, selling wholesale to eye care professionals and optical retailers across Europe, Asia-Pacific, and Canada.
- Company typePrivate
- Founded2016
- HeadquartersPalo Alto, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What SightGlass Vision does
Short text here
SightGlass Vision firmographics
Firmographics- Name
- SightGlass Vision
- Legal name
- SightGlass Vision, Inc.
- Website
- https://sightglassvision.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- SightGlass Vision is a medical device company that develops DOT (Diffusion Optics Technology) spectacle lenses to slow myopia progression in children aged 6–13, selling wholesale to eye care professionals and optical retailers across Europe, Asia-Pacific, and Canada.
- Ownership category
- akta.pro rank
SightGlass Vision industry classification
Industry- Product category
- Myopia Control Spectacle Lenses
- NAICS
- Ophthalmic Goods Manufacturing (339115)
- SIC
- Ophthalmic Goods (3851)
- akta.pro primary industry
- Optical Dispensing & Eyewear Devices (Frames, Lenses, Lens Edging/Finishing Equipment) (HLAHAJAD)
- akta.pro secondary industry
- Pediatric Ophthalmology & Orthoptics Devices (Amblyopia Therapy, Strabismus Measurement & Treatment) (HLAHAJAM)
Keywords
Where SightGlass Vision is headquartered
LocationHeadquarters
- HQ city
- Palo Alto
- HQ country
- United States
- HQ region
- North America
Offices5 records
Markets served
SightGlass Vision business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Marketing or Sales, Supply Chain, Personnel, Operations
Revenue model
- DOT Spectacle Lens Sales (B2B): SightGlass Vision sells its DOT spectacle lenses to eye care professionals (optometrists, opticians, ophthalmologists) and optical retailers on a wholesale B2B basis. Eye care professionals then dispense the lenses to patients (children with myopia). Revenue is generated through product sales to the trade, with pricing governed by contracts and price lists. Products are distributed via approved sales channels in markets where commercially available.
- Professional Services and Training: The company provides professional education, clinical resources, and training materials to eye care professionals to support adoption and correct fitting of DOT lenses. This supports the core product revenue stream by driving prescription volumes.
Go-to-market motion3 records
Distribution channels4 records
Marketing channels8 records
SightGlass Vision product offering
Product offeringCore offering
SightGlass Vision develops and commercializes DOT (Diffusion Optics Technology) spectacle lenses designed to slow myopia progression in children aged 6-13. The lenses integrate thousands of light-scattering micro-dots that reduce artificial contrast signals reaching the retina, addressing the root cause of childhood myopia. Products are manufactured and distributed through channel partners and the joint venture's global optical infrastructure, with clinical backing from multi-year trials showing up to 75% reduction in myopia progression after 12 months of wear.
Product overview
SightGlass Vision offers a single unified product: DOT™ (Diffusion Optics Technology™) spectacle lenses for myopia control in children. The flagship product integrates thousands of light-scattering elements called dots that mimic natural contrast at all distances. The lenses correct vision while simultaneously slowing myopia progression through contrast management. The product has completed the pivotal three-year CYPRESS multi-site clinical study and is available in markets including China, Canada, Netherlands, Israel, Spain, and the U.K. The company operates as a joint venture of CooperCompanies and EssilorLuxottica. SightGlass Vision does not sell products in the United States.
Differentiator
Problem solved
Functional benefit
Brands
- DOT (Diffusion Optics Technology): DOT spectacle lenses use thousands of light scattering elements called dots that mimic more natural contrast on the retina to slow myopia progression in children.
Products and services
- DOT (Diffusion Optics Technology) Spectacle Lenses Prescription spectacle lenses integrating thousands of light-scattering micro-dots that reduce retinal contrast to slow myopia progression in children aged 6-13. Dispensed exclusively through qualified eye care professionals (optometrists, dispensing opticians, ophthalmologists).
- DOT 0.2 Spectacle Lenses Specific DOT lens variant with a 0.2 diffusion level used in the CYPRESS (North American) and CATHAY (Chinese) clinical trials, demonstrating up to 75% reduction in myopia progression after 12 months in children aged 6-13.
Quantifiable outcome
- 75% reduction in cycloplegic spherical equivalent refraction (cSER) progression after 12 months of wear in Chinese children (CATHAY trial)
- +7 more outcomes
Companies that use SightGlass Vision
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles2 records
SightGlass Vision technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
SightGlass Vision partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Nikon LenswearcoreNikon Lenswear is the exclusive commercial partner for DOT lens distribution in China, announced at COOC 2023. SightGlass Vision and Nikon Lenswear co-present at COOC, with Nikon handling local commercialization of DOT lenses in China. Nikon Lenswear and SightGlass Vision collaborate on product demonstrations, case reviews, and clinical trial result presentations with Chinese eye care key opinion leaders.
Scale indicators8 records
Recent moves5 records
Expansion highlights6 records
SightGlass Vision competitors and assessment
Company assessmentDirect peers
- HOYA Corporation (MiyoSmart): HOYA's MiyoSmart uses DIMS (Defocus Incorporated Multiple Segments) technology to slow myopia progression in children via spectacle lenses — the closest direct competitor to SightGlass Vision's DOT, targeting the same pediatric population and ECP channel with a different optical mechanism.
- EssilorLuxottica (Stellest lenses): Essilor's Stellest spectacle lenses, built on highly aspherical lenslet technology, compete head-to-head with DOT in pediatric myopia control. EssilorLuxottica is also a parent JV partner of SightGlass Vision, creating both collaboration and channel-conflict dynamics.
- CooperVision (MiSight): CooperVision's MiSight 1 day is the first FDA-approved contact lens for myopia control in children and is the leading non-spectacle alternative. CooperVision distributes DOT in Canada and is also a parent JV partner of SightGlass Vision, situating it as both peer and partner.
Emerging players
- Menicon (Miru): Menicon has developed myopia control contact lenses and orthokeratology solutions targeting the same pediatric population. As an emerging player with growing clinical data, it overlaps with DOT in indication and prescriber base.
- Ocumetra: Ocumetra provides myopia management software, risk calculators, and outcome simulation tools for eye care professionals — including hosting the DOT Vision Simulator on SightGlass Vision's website. It targets the same ECP/pediatric-myopia workflow as DOT.
- Eyerising International: Eyerising develops repeated low-level red-light therapy devices for childhood myopia control, representing an emerging non-lens intervention that intersects with DOT's pediatric myopia indication at the ECP-prescription layer.
Broad incumbents
- Johnson & Johnson Vision: J&J Vision is a broad incumbent in contact lenses and pediatric vision care. Its recent moves into myopia management overlap with DOT's target market of children with progressive myopia.
- Bausch + Lomb: Bausch + Lomb offers vision care products including contact lenses and ophthalmic devices, with interests in myopia management, serving overlapping ECP and pediatric patient populations as DOT.
- Carl Zeiss Meditec: Zeiss produces ophthalmic devices, lens coatings, and vision diagnostics. As a broad incumbent in optical instrumentation and lens technology, it is comparable to SightGlass Vision in the ophthalmic device and eyewear technology space.
Regional players
- Nikon Lenswear: Nikon Lenswear is the exclusive distribution partner for DOT lenses in China and produces its own corrective spectacle lenses. It serves the same pediatric myopia market in a specific geography and is both a commercial partner and adjacent competitor to SightGlass Vision.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
SightGlass Vision social profiles
Digital presenceSightGlass Vision financial estimates
Financial estimateRevenue estimate
Valuation estimate
SightGlass Vision leadership team
Management profileNumber of profiles
Profiles7 records
SightGlass Vision subsidiaries and ownership
Company hierarchySubsidiaries1 record
SightGlass Vision funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SightGlass Vision M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SightGlass Vision
What does SightGlass Vision do?
SightGlass Vision develops and commercializes DOT (Diffusion Optics Technology) spectacle lenses designed to slow myopia progression in children aged 6-13. The lenses integrate thousands of light-scattering micro-dots that reduce artificial contrast signals reaching the retina, addressing the root cause of childhood myopia. Products are manufactured and distributed through channel partners and the joint venture's global optical infrastructure, with clinical backing from multi-year trials showing up to 75% reduction in myopia progression after 12 months of wear.
Is SightGlass Vision a public or private company?
SightGlass Vision is a private company. It is classified as corporate owned and is currently operating.
When was SightGlass Vision founded?
SightGlass Vision was founded in 2016. It employs 1 to 10 people.
Where is SightGlass Vision based?
SightGlass Vision is headquartered in Palo Alto, United States, in the North America region.
How does SightGlass Vision make money?
Two revenue lines are on record. DOT Spectacle Lens Sales (B2B) is the primary driver. The others are professional Services and Training.
Who are SightGlass Vision's main competitors?
Direct peers on record are HOYA Corporation (MiyoSmart), EssilorLuxottica (Stellest lenses) and CooperVision (MiSight). Emerging players are Menicon (Miru), Ocumetra and Eyerising International. Broad incumbents are Johnson & Johnson Vision, Bausch + Lomb and Carl Zeiss Meditec. Nikon Lenswear is listed as a regional player.
Does SightGlass Vision have an API?
No public API is recorded for SightGlass Vision.
What industry is SightGlass Vision in?
SightGlass Vision's product category is Myopia Control Spectacle Lenses. Its primary akta.pro industry code is HLAHAJAD, Optical Dispensing & Eyewear Devices (Frames, Lenses, Lens Edging/Finishing Equipment), with a secondary code of HLAHAJAM, Pediatric Ophthalmology & Orthoptics Devices (Amblyopia Therapy, Strabismus Measurement & Treatment). Its NAICS code is 339115 and its SIC code is 3851.